ArticlebioRxiv : the preprint server for biology2025
Coupled SDE-ODE Modeling of Tumor-Immune Dynamics to Infer Biomarker Release.
Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
3 authors.
Funding
Abstract
Tumor-immune interactions are central to cancer progression and treatment response, driving cell death through immune-mediated killing and resource-limited competition. In early-stage disease or following effective treatment, cancer populations are often small and difficult to observe directly. Disease monitoring therefore relies on the detection of biomarkers such as circulating tumor DNA (ctDNA) as noisy proxies to cancer size. However, existing approaches lack robust frameworks to infer tumor burden from these signals when populations approach detection thresholds. To address this, we present a coupled deterministic-stochastic framework that links tumor-immune dynamics to biomarker release. A two-prey, one-predator Lotka-Volterra model captures interactions between immune cells and competing tumor subpopulation under shared resource constraints. Biomarker production is modeled using a linear stochastic differential equation, incorporating ctDNA release from both apoptotic death (immune-mediated) and necrotic death (due to intra-tumor competition). We derive analytical solutions for the resulting biomarker trajectories, including mean detection time under a minimal detection threshold. These results show how volatility in measured biomarker signal, disease heterogeneity, and immune pressure jointly shape signal emergence and persistence. Finally, to model situations in which the observer has access to future information-such as the terminal biomarker signal or sampling time in retrospective studies-we adopt an anticipative theoretic perspective. Using anticipative stochastic calculus, we derive path solutions to the resulting anticipating stochastic differential equation, capturing how future observations influence the inferred biomarker dynamics. This approach links the dynamics of underlying tumor-immune interactions to the corresponding detectable biomarker levels, with implications for early detection, immune monitoring, and retrospective reconstruction of disease progression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.